- More than 80 percent of MS specialists in the U.S. have prescribed AUBAGIO;
- Approximately 1 in 5 patients prescribed AUBAGIO were treatment-naïve;
- More than 50 percent of AUBAGIO patients were most recently on Copaxone ® or Avonex ®
The technology could mean banks would not necessarily have to move to the EU.
The Big 6 U.K. bank will focus on regulatory challenges following the Brexit vote.